Ascites Hepatic, Cirrhosis, Liver
Conditions
Keywords
Cirrhosis, Ascites, Refractory ascites, Natriuresis, Diuresis, Urodilatin, Ularitide, natriuretic peptide
Brief summary
This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind, single-center trial.
Detailed description
The investigators hypothesize that ularitide infusion is more effective than placebo to induce and maintain clinically meaningful natriuresis and diuresis in patients with liver cirrhosis and refractory ascites. Participants will be given ularitide or placebo intravenously while hospitalized at Department of Hepatology and Gastroenterology at Aarhus University Hospital. During the hospitalization blood and urine samples are frequently collected. 30 ng/kg/min is the starting dosage for all participants. Depending on effects and/or side effects, ULA04 is designed to individualize treatment doses by up- and/or downtitration of the infusion dose within a predefined dose range. Relevant safety precautions are incorporated in the study design and treatment will be prematurely discontinued if a pre-defined stopping criteria presents. Patients will be followed up for the appearance of serious adverse events 30 days after the treatment. If a separate written consent is given by the participants, additional blood and urine samples will be collected and stored in a biobank for future research.
Interventions
DRUGUlaritide
Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
DRUGPlacebo
Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
Sponsors
Aarhus University Hospital
ADS AIPHIA Development Services AG
University of Aarhus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Randomized, double-blind, placebo-controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women \>18 years * Liver cirrhosis confirmed by fibroscan (\>20 kPa), or by imaging with signs of an irregular liver surface with collaterals, or clinically by cirrhosis stigmata * Refractory ascites Definition: failure to respond to or intolerance to high dose diuretics (spironolactone up to 400mg/day and furosemide up to 160mg/day) and early ascites recurrence (reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization or ≥2 paracentesis within last 3 months) * Urine sodium excretion \<60 mmol/24 hour * Serum creatinine \<150 µmol/L * Child-Turcotte-Pugh score of B or C (\<13) * Bilirubin \<150 µmol/L * Prothrombin time (PP) 0.20-0.60 (INR 1.3-2.5) * Systolic blood pressure ≥95 mmHg * Written informed consent to participate in the clinical trial
Exclusion criteria
* Gastrointestinal bleeding within 2 weeks prior to inclusion * Proteinuria \>500 mg/day * Hemoglobin \<5.5 mmol/L * Spontaneous bacterial peritonitis within 2 weeks prior to inclusion * Loculated ascites * Hepatic encephalopathy grade 2-4 (West-Haven classification) * Obstructive uropathy * Primary kidney disease * Known diagnosis of congestive heart failure * Known diagnosis of acute-on-chronic liver failure * Known diagnosis of systemic inflammatory response syndrome * Acute infections by known diagnosis and/or antibiotic treatment * Known HIV infection * Known allergy to the investigational drug or other natriuretic peptides * Treatment with dobutamine, levosimendan, milrinone, any phosphodiesterase inhibitor, octreotide, midodrine, vasopressin, dopamine or other vasopressors within 2 weeks prior to inclusion * Nephrotoxic drugs within 1 month prior to inclusion * Fertile women not using contraception, either an intrauterine device or hormonal contraception * Positive pregnancy test in pre-menopausal women or in breast-feeding women * Participation in an interventional clinical drug trial within 1 month prior to inclusion * Legal incapacity or limited legal capacity * Patients who are employees or relatives of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of absolute body weight. | At termination of treatment (up to 48 hours) |
| Absolute and relative change in urine volume. | After 24 hours and at termination of treatment (up to 48 hours) |
| Absolute and relative change in sodium excretion rate. | After 24 hours and at termination of treatment (up to 48 hours) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute and relative change in urine volume. | After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma cyclic guanosine monophosphate (cGMP) concentration. | Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up | — |
| Absolute and relative change in waist circumference. | After 24 hours and at termination of treatment (up to 48 hours) | — |
| Absolute and relative change in serum creatinine. | After 24 hours and at termination of treatment (up to 48 hours) | — |
| Absolute and relative change in estimated glomerular filtration rate (eGFR). | After 24 hours and at termination of treatment (up to 48 hours) | — |
| Number of responders in the ularitide group versus the placebo group, defined by: | Throughout the treatment period. Latest measure at termination of treatment (up to 48 hours) | Urine volume increase of ≥100 % versus baseline, urine volume increase ≥50 % versus baseline, natriuresis increase by ≥100 % versus baseline and/or body weight reduction by ≥2 kg versus baseline. |
| Absolute and relative change in sodium excretion rate. | After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma copeptin concentration. | After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma renin concentration. | After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma angiotensin concentration. | After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma aldosterone concentration. | After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up | — |
| Absolute and relative change in plasma and urine osmolalities. | Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up | — |
| Absolute and relative change in GFR-24h-Crea (Glomerular filtration rate based on 24-hour creatinine clearance). | After 24 hours and 48 hours of treatment | — |
| Absolute and relative change in hematocrit. | After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up | — |
Other
| Measure | Time frame |
|---|---|
| Incidence of adverse events/reactions. | Throughout the treatment period and until 6 hours post-treatment follow-up |
| Incidence of serious adverse events/reactions. | Throughout the treatment period and until 30 days post-treatment follow-up |
| Incidence of stopping criteria leading to early termination of treatment. | Throughout the treatment period (up to 48 hours) |
| Incidence of stopping criteria leading to a dose reduction. | Throughout the treatment period (up to 48 hours) |
Countries
Denmark
Outcome results
None listed